Activates Toll-like receptor 9 on plasmacytoid dendritic cells, restoring T-helper 1 immunity in immunocompromised states.
Reference facts
- Also known as
- Tα1, Zadaxin, Thymalfasin
- Category
- Immune Modulator
- Mechanism of action
- Activates Toll-like receptor 9 on plasmacytoid dendritic cells, restoring T-helper 1 immunity in immunocompromised states.
- Targets
- TLR9, T-cell maturation
- Indications under research or approved
- Hepatitis B (approved 35+ countries), Hepatitis C, sepsis, immune support in cancer (off-label/research)
- Regulatory status (reference entry)
- Not FDA-approved (orphan drug status; approved in EU, Asia)
- Half-life
- ~2 hours
- Sequence
- SDAAVDTSSEITTKDLKEKKEVVEEAEN
- Sequence notes
- 28-residue acetylated peptide derived from prothymosin alpha; N-terminal acetylated.
- Molecular weight (Da)
- 3108
- Originator / sponsor
- SciClone Pharmaceuticals
- First reported
- 1972
Primary References
Explore research articles about Thymosin Alpha-1
This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.